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Abstract
Rationale: A better understanding of the composition of optimal treatment regimens for multidrug-resistant tuberculosis
(MDR-TB) is essential for expanding universal access to effective treatment and for developing new therapies for MDR-TB.
Analysis of observational data may inform the definition of an optimized regimen.
Objectives: This study assessed the impact of an aggressive regimen–one containing at least five likely effective drugs,
including a fluoroquinolone and injectable–on treatment outcomes in a large MDR-TB patient cohort.
Methods: This was a retrospective cohort study of patients treated in a national outpatient program in Peru between 1999
and 2002. We examined the association between receiving an aggressive regimen and the rate of death.
Measurements and Main Results: In total, 669 patients were treated with individualized regimens for laboratory-confirmed
MDR-TB. Isolates were resistant to a mean of 5.4 (SD 1.7) drugs. Cure or completion was achieved in 66.1% (442) of patients;
death occurred in 20.8% (139). Patients who received an aggressive regimen were less likely to die (crude hazard ratio [HR]:
0.62; 95% CI: 0.44,0.89), compared to those who did not receive such a regimen. This association held in analyses adjusted
for comorbidities and indicators of severity (adjusted HR: 0.63; 95% CI: 0.43,0.93).
Conclusions: The aggressive regimen is a robust predictor of MDR-TB treatment outcome. TB policy makers and program
directors should consider this standard as they design and implement regimens for patients with drug-resistant disease.
Furthermore, the aggressive regimen should be considered the standard background regimen when designing randomized
trials of treatment for drug-resistant TB.
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Introduction
Multidrug-resistant strains of Mycobacterium tuberculosis accounted
for approximately 5% of the 6.2 million tuberculosis (TB) cases
notified in 2011. [1] Treatment for multidrug-resistant tubercu-
losis (MDR-TB) typically lasts between 18 and 24 months, and
adverse events are common. [2] The combined frequency of cure
and completion often remains below 65%. [3,4,5] Even when
therapy is designed with access to the full complement of anti-TB
agents presently available, outcomes rarely approach the target for
TB treatment success (cure at least 85% of patients initiating
therapy). [6,7] The long duration and toxicity of current MDR-
TB regimens are major obstacles to achievement of universal
access to quality treatment. [8,9] In addition, the poor outcomes
seen with current regimens mean that, despite treatment, many
MDR-TB patients will still develop chronic, highly resistant forms
of TB that have a high mortality rate and can be transmitted to
others. [10,11].
For drug-resistant TB, improved treatment depends on in-
troduction of new drugs and optimal use of existing drugs.
Guidance about the use of drugs in MDR-TB regimens has been
based on expert opinion, and most recently on GRADE
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Nevertheless, controversies persist about optimal regimen con-
struction and duration. [6,14,15] Additional experience from
observational treatment cohorts can inform the composition of
optimal regimens.
One influential approach to the composition of regimens
recommends a minimum of five drugs to which the isolate was
documented or likely to be susceptible. This approach, to
composing what we call an ‘‘aggressive’’ regimen, was presented
in a 2004 article [16] and used as the foundation for WHO
guidelines. [13,17,18,19] To reach the five-drug minimum, the
algorithm recommends inclusion of first-line agents, an injectable
agent, a fluoroquinolone, and then any of the agents with
documented bacteriostatic activity against M. tuberculosis including
ethionamide/prothionamide, cycloserine/terizidone, and PAS. If
a total of five likely effective drugs cannot be reached using these
agents, the aggressive regimen also includes other agents of
possible utility such as clofazimine, amoxicillin-clavulanate, and/
or a macrolide antibiotic. This regimen was recommended to be
delivered for 18–24 months past culture conversion, with the
injectable agent being administered for 6 months after culture
conversion.
Despite having had such an important impact on policy and
guidelines, the effectiveness of this aggressive regimen–compared
to the effectiveness of regimens not constructed according to this
algorithm–has never been explicitly evaluated. The present
retrospective, observational study evaluates whether this algo-
rithm-based aggressive regimen was associated with a decreased
rate of death when administered to patients with MDR-TB in
Peru from 1999–2002. [16].
Methods
Study Population
The retrospective cohort included all patients who were
enrolled between 1 February 1999 and 31 July 2002 in Lima,
Peru, in ambulatory treatment for MDR-TB, which was tailored
or individualized to each patient’s drug-susceptibility test (DST)
results (N=673). Patients were excluded from analysis either if (a)
if the regimen delivered during the observational study period was
not their first individualized MDR-TB treatment or (b) data on
regimen composition were not available. We have previously
reported on this cohort. [20,21,22,23] Patients received care from
a consortium led by the National TB Program. The consortium,
which included the non-governmental organization Partners In
Health (Socios En Salud-Sucursal Peru), scaled up this ambulatory
program throughout metropolitan Lima during the study period.
Treatment and Monitoring
Baseline evaluation, DST, and treatment monitoring were
performed as described previously. [24] DST to the first-line drugs
(isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin)
was routinely performed. In more than 75% of patients, DST was
also performed to the following second-line drugs: amikacin,
capreomycin, cycloserine, ethionamide, kanamycin, para-amino-
salacylic acid; ciprofloxacin or ofloxacin; and either gatifloxacin,
levofloxacin, or moxifloxacin. Fewer than 25% of patients had
isolates tested to other agents: amoxicillin-clavulanic acid,
clofazimine, clarithromycin, or rifabutin. All patients who met
the inclusion criteria specified above were included, regardless of
the extent of DST performed on their infecting isolates.
Regimens were constructed using DST results and prior
treatment exposure according to previously described principles.
[16].
Outpatient treatment was directly observed, either at public-
health centers or in patients’ homes, by community-health workers
or nurses. Adverse events were managed by these workers
according to established algorithms [25,26] in consultation with
physicians from the National TB Program consortium. Adjunct
medical services (including thoracic surgery) and psycho-social and
nutritional support were provided to patients free of charge as
deemed necessary by expert providers. [24,25,27,28,29].
Data Collection, Primary Exposure, Covariates and
Outcome Definitions
Data were collected and recorded in a web-based electronic
medical record during treatment. [30] A standardized paper chart
abstraction was conducted to complete the dataset.
The primary exposure variable was receipt of an aggressive
regimen. We classified the regimen as aggressive in the intensive
phase if it contained at least five antituberculosis agents–including
one of the injectable agents (streptomycin, kanamycin, capreomy-
cin, amikacin) for at least six months after culture conversion and
one fluoroquinolone–that met criteria suggesting efficacy accord-
ing to the individual’s baseline DST and treatment history. The
continuation phase of the aggressive regimen contained at least
four likely effective oral drugs (including a fluoroquinolone). [16]
An agent was considered efficacious if either (1) all in vitro
sensitivity testing prior to the start of this regimen confirmed
susceptibility to the agent used; or, (2) in vitro sensitivity testing to
the agent was not available and the patient had not received the
agent for .1 month prior to individualized treatment.
Exposure to an aggressive regimen was assessed for each
treatment day because regimen adjustments could change
exposure status. Changes occurred occasionally by design–regi-
mens were started empirically and then adjusted when baseline
DST results became available–and in response to adverse events,
non-response to therapy, and drug stockouts. If at least 75% of
regimen days in a month met the aggressive regimen definition,
then the treatment month was coded as exposed; otherwise, the
treatment month was coded as unexposed.
Covariates. Previous treatment was an important covariate
abstracted from the record. There was significant variability in
prior TB treatment regimens among the study participants. This
included differences in numbers of prior regimens and contents of
prior regimens: first-line drugs only or first- and second-line drugs;
the latter were contained in the standardized regimen for MDR-
TB (which was implemented by the National TB Program in 1997
[31]). To simplify, in the present analysis, prior TB treatment was
dichotomized into two levels: (i) less prior treatment: 2 or fewer
prior regimens, not including the standardized regimen for MDR-
TB and (ii) more prior treatment: more than 2 regimens or prior
treatment with the standardized regimen for MDR-TB.
Other variables collected include: demographics (age, sex,
location of residence, treatment time period); all DST results at or
prior to initiation of the individualized regimen (distribution of
resistance is reported out of the 12 agents/drug classes listed
above). Indicators of disease severity were collected including:
hematocrit, nutritional status (body mass index [BMI] and clinical
diagnosis of malnutrition), presence of extrapulmonary TB,
respiratory difficulty (dyspnea or resting respiratory rate .26/
minute), tachycardia (heart rate .100/minute), cavitary and
bilateral disease on chest radiography. Comorbidities and risk
factors–substance and tobacco use, human immunodeficiency
virus infection, diabetes mellitus, cardiovascular and renal disease,
and psychiatric and seizure disorders–were recorded.
Outcomes. Treatment outcomes (cure, completion, failure,
death) were defined as previously described. [32] The primary
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regimen to death from any cause, while on treatment. Data were
censored when an outcome other than death was recorded.
Analysis
We modeled the association between receiving an aggressive
regimen for at least 75% of the days in the current month and the
hazard of death using Cox proportional hazards analysis. [33]
Subjects were excluded from analyses if data were missing about
the composition of the regimen.
Each covariate (prior treatment, sex, age, extent of disease on
chest radiography, extent of resistance [number of drugs, XDR-
TB], disease severity, and comorbidities) was evaluated for
association with hazard of death.
Those variables that predicted the outcome at a p value #0.10
were considered candidates for the multivariate model. We
retained a candidate variable in the final model if it remained
associated with hazard of death at a p value #0.05 or if inclusion
of that variable changed the effect estimate of aggressive in the
model by $10%. We included age and sex in the final
multivariable model due to their strong established link with poor
outcomes from tuberculosis. We evaluated the possibility that the
effect of an aggressive regimen was different in patients with
confirmed extensively drug resistant TB (XDR-TB, TB caused by
strains of M. tuberculosis resistant to at least isoniazid, rifampin,
a fluoroquinolone, and a second-line injectable agent), compared
to those without XDR-TB (effect modification), by including an
interaction term in the multivariable analysis.
The proportional hazards assumption was tested by examining
the interaction between the time-varying aggressive regimen
variable and the treatment semester. Informative censoring was
assessed by evaluating the association between default and the
aggressive regimen. Missing values were multiply imputed using
Markov Chain Monte Carlo methods to complete the dataset. All
statistical tests were two-sided. Analyses were conducted using SAS
version 9.12 (The SAS Institute, Cary, North Carolina).
This retrospective study was approved by the Committee on
Human Studies at Harvard Medical School and by the Ministry of
Health of Peru. Since the analysis was carried out using data that
had been collected routinely under the aegis of the Peruvian
National TB Program, informed consent was not required by the
ethics boards.
Results
Two patients were excluded because the regimen received
during the study period was not their first individualized regimen
for MDR-TB; two were excluded from analysis because details on
the composition of their regimen were unavailable. Analyses were
performed on data from 669 patients.
At initiation of the individualized regimen, patient isolates were
resistant to a mean of 5.4 (SD 1.7) drugs; 48 (7.2%) had XDR-TB.
One hundred seventy-three (25.9%) patients had received two or
fewer previous regimens, not including the standardized regimen
for MDR-TB; two patients had never received TB treatment.
Respiratory difficulty (72.2%) and bilateral, cavitary disease
(55.3%) were the most common indicators of severity. Documen-
ted HIV coinfection was rare, occurring in only 10 (1.5%) patients.
Other comorbidities were more common: 233 (36.4%) patients
had at least one other comorbidity (Table 1).
The median duration of the regimen was 24.4 (inter-quartile
range [IQR]: 19.4–27.8) months. Among those who received an
aggressive regimen for at least one month (547 [82%]), the median
duration of that regimen was 21 (IQR: 15–26) months. Of note,
among the 48 patients with confirmed XDR-TB, 28 (58%)
received an effective regimen during at least one month.
Outcomes were available for 665 patients. Cure or completion
was achieved in 442 (66.1%) while death occurred in 139 (20.8%)
(Table 2).
In a time-varying univariate analysis, receiving more than 75%
of doses of an aggressive regimen in a month was associated with
a decreased hazard of death (HR: 0.62; 95% CI: 0.44,0.89). Less
prior treatment at baseline was also associated with decreased rate
of death (p,0.01). Baseline characteristics–increased age, bilateral
and cavitary disease on chest radiography, a number of indicators
of severity, comorbities (other than HIV), and HIV–were all
significantly associated with increased rate of death (p,0.05).
XDR-TB was not associated with any elevated risk (p=1.00);
however an increase in the number of drugs to which the isolate
was resistant was associated with increased rate of death (p,0.01)
(Table 3). In multivariable analysis (Table 4), exposure to an
aggressive regimen in a month was independently associated with
decreased rate of death (HR: 0.63; 95% CI: 0.43,0.93); in all
semesters of treatment, the effect of an aggressive regimen
remained protective. Less prior TB therapy (HR: 0.43; 95% CI:
0.25,0.74) was also associated with decreased rate of death. Low
BMI (HR: 2.45; 9 5% CI: 1.63,3.68), and tachycardia (HR: 2.19;
95% CI: 1.50,3.19) were independently associated with increased
rate of death. Women were also at increased risk of death (HR:
1.45; 95% CI: 1.02,2.07). When we compared the benefit of
receiving an aggressive regimen in patients with confirmed XDR-
TB and those without XDR-TB, we found no difference.
Therefore, the interaction term was excluded from the final
multivariable model. Censoring due to default was not associated
with exposure to the aggressive regimen.
Discussion
Here we test the utility of an operational definition of an
aggressive regimen for treating MDR-TB. We previously proposed
an algorithm for MDR-TB regimen design; this entailed,
preferentially, any first-line drugs to which the isolate was sensitive,
an injectable for at least 6 months after culture conversion,
a fluoroquinolone, and a complement of bacteriostatic second-line
drugs to reach the target of five. [16] In accordance with this
algorithm, for the present analysis, we specified that an aggressive
regimen had the following characteristics: at least five likely
efficacious drugs, including a fluoroquinolone and injectable in the
intensive phase; in the continuation phase, the requirement was at
least four likely efficacious drugs, including a fluoroquinolone.
Exposure to an aggressive regimen was time-varying due to drug
changes during the course of treatment. Ignoring this variability,
or requiring a minimum duration of exposure to the regimen for
classification as aggressive, would result in misclassification of
exposure. [34] The consequence could be biased effect estimates,
in some cases overestimating the benefits of an aggressive regimen.
[35] We therefore evaluated the effect of monthly exposure to an
aggressive regimen on death rate.
In this large, well-characterized treatment cohort in Peru, we
found that receipt of a regimen that met all of these criteria was
a robust predictor of successful MDR-TB treatment outcome in
the face of all measured covariates. These results complement our
recent finding that receipt of an aggressive regimen for at least 18
months was associated with a lower rate of recurrent TB. [23]
Even after controlling for risk factors such as extensive prior anti-
TB treatment, advanced age, poor nutritional status, and
indicators of advanced disease such as tachycardia, the rate of
death was nearly halved in each month in which patients received
Aggressive MDR-TB Regimens Save Lives
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patients with XDR-TB to the others, we found that, unsurpris-
ingly, aggressive regimens were less likely to be constructed in the
XDR-TB group. However, most (31) XDR-TB patients could
receive at least one injectable to which their isolate was not
confirmed to be resistant and all could receive at least one
fluoroquinolone to which their isolate was not resistant. The
benefits associated with receiving an aggressive regimen were also
observed in the XDR-TB group.
It is noteworthy that several other factors were independently
associated with death. These included having received extensive
prior treatment–at least 2 previous treatments with or without the
standardized regimen for MDR-TB. This effect may have been
mediated through resistance, which is known to be a consequence
of repeated TB treatment. [36] Receipt of fewer prior regimens
reduced the rate of death by almost half and likely reflects, in part,
less resistance. And, avoiding ineffective regimens can result in less
disease severity–also independently associated with increased rate
of death–and less cumulative toxicity from anti-TB treatment. For
all these reasons, and to preserve program resources, minimizing
exposure to inadequate regimens should be a priority of TB
treatment programs. To this end, current program policy in Peru
is to screen all TB patients for resistance; [37] this is a change from
the policy in place at the time the present study was conducted,
which called for resistance testing only after failure of at least two
TB regimens. Additional attention to gender–among other social
determinants of health–and MDR-TB may also be necessary since
these findings corroborate our earlier non-significant findings of
increased risk of poor outcomes among women with MDR-TB
Table 1. Distribution of covariates at initiation of ITR.
COVARIATE N=669 Patients with specified characteristics
N (%) or Mean (SD)
PRIOR TREATMENT
Received #2 previous regimens without CER 668 173 (25.9)
DEMOGRAPHICS
Female 669 261 (39.0)
Age
1 668 31.4 (12.1)
Enrolled in Northern Lima 669 274 (41.0)
Enrolled prior to March 1, 2001 669 155 (23.2)
INDICATORS OF SEVERITY
Bilateral, cavitary findings 637 352 (55.3)
Low BMI
2 or malnutrition 573 225 (39.3)
Low hematocrit
3 584 287 (49.1)
Tachycardia 652 196 (30.1)
Respiratory difficulty
4 632 456 (72.2)
Extrapulmonary TB 668 60 (9.0)
Number of resistant agents
5 669 5.4 (1.7)
Lab-confirmed XDR-TB
6 669 48 (7.2)
Prior resective surgery 648 18 (2.8)
COMORBITIES
Patients with at least one comorbidity
7 640 233 (36.4)
HIV infection 656 10 (1.5)
1Continuous variable, mean (standard deviation) presented.
2,18.5 in women; ,20 in men; or malnutrition established clinically.
3#30% in women; #36% in men; when missing, also used hemoglobin #10 in women and #12 in men.
4Dyspnea; resting respiratory rate greater than 26/minute.
5Resistance to the following 12 drugs or drug classes was tested: capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, kanamycin or amikacin, PAS,
pyrazinamide, rifampicin, streptomycin, first-generation fluoroquinolones (ciprofloxacin, ofloxacin), and later-generation fluoroquinolones (gatifloxacin, levofloxacin,
moxifloxacin).
6Isolate resistant to at least isoniazid, rifampin, fluoroquinolone, and injectable (kanamycin, capreomycin, or amikacin).
7This includes the following comorbidities: cardiovascular disease (12), diabetes mellitus (18), hepatitis or cirrhosis (10), epilepsy/seizures (11), renal insufficiency (7),
psychiatric disorder (116), ever smoked (66), ever used/abused alcohol or other substance (52).
doi:10.1371/journal.pone.0058664.t001
Table 2. Treatment outcomes of 669 patients enrolled in
individualized treatment for MDR-TB in Peru between
February 1999 and July 2002. (Adapted from Mitnick et al.,
2008) [20].
Outcome N (%)
Cured/Completed 442 (66.1)
Treatment Failed 17 (2.5)
Died 139 (20.8)
Defaulted 67 (10.0)
Missing/Transferred Out 4 (0.6)
Total 669 (100)
doi:10.1371/journal.pone.0058664.t002
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found an increased risk of poor outcomes among men. [38] Lastly,
attention to improved diagnostics and treatment of HIV coinfected
patients and patients with extrapulmonary MDR-TB is indicated
by this study. None of these patients was receiving ART. These
findings build on those that have previously identified an increased
risk of mortality among MDR-TB patients with HIV coinfection.
[39,40] Prior work has demonstrated that this increased risk can
Table 3. Univariate, time-varying Cox proportional hazards analysis of aggressive regimen and time to death.
COVARIATE Hazard ratio, univariate analysis 95% CI, univariate analysis p-value
Monthly exposure to aggressive regimen 0.62 0.44, 0.89 0.01
PRIOR TREATMENT
Received #2 previous regimens without CER 0.36 0.21, 0.61 ,0.01
DEMOGRAPHICS
Female 1.25 0.89, 1.76 0.19
Age
1 1.02 1.00, 1.03 0.01
Enrolled in Northern Lima 0.71 0.50, 1.01 0.06
Enrolled prior to March 1, 2001 1.11 0.74, 1.66 0.63
INDICATORS OF SEVERITY
Bilateral, cavitary findings 2.15 1.46, 3.16 ,0.01
Low BMI
2 or malnutrition 4.29 2.89, 6.36 ,0.01
Low hematocrit
3 2.24 1.53, 3.27 ,0.01
Tachycardia 3.21 2.29, 4.49 ,0.01
Respiratory difficulty
4 4.70 2.54, 8.72 ,0.01
Extrapulmonary TB 2.82 1.84, 4.33 ,0.01
Number of resistant agents
5 1.17 1.06, 1.28 ,0.01
Lab-confirmed XDR-TB
6 1.00 0.54, 1.86 1.00
Prior resective surgery 1.49 0.61, 3.65 0.38
COMORBITIES
Patients with at least one comorbidity
7 1.99 1.41, 2.81 ,0.01
HIV infection 3.16 1.29, 7.74 0.01
1Continuous variable, mean (standard deviation) presented.
2,18.5 in women; ,20 in men; or malnutrition established clinically.
3#30% in women; #36% in men; when missing, also used hemoglobin #10 in women and #12 in men.
4Dyspnea; resting respiratory rate greater than 26/minute.
5Resistance to the following 12 drugs or drug classes was tested: capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, kanamycin or amikacin, PAS,
pyrazinamide, rifampicin, streptomycin, first-generation fluoroquinolones (ciprofloxacin, ofloxacin), and later-generation fluoroquinolones (gatifloxacin, levofloxacin,
moxifloxacin).
6Isolate resistant to at least isoniazid, rifampin, fluoroquinolone, and injectable (kanamycin, capreomycin, or amikacin).
7This includes the following comorbidities: cardiovascular disease (12), diabetes mellitus (18), hepatitis or cirrhosis (10), epilepsy/seizures (11), renal insufficiency (7),
psychiatric disorder (116), ever smoked (66), ever used/abused alcohol or other substance (52).
doi:10.1371/journal.pone.0058664.t003
Table 4. Multivariable, time-varying Cox proportional hazards analysis of aggressive regimen and time to death.
Variable Hazard ratio, multivariable analysis 95% CI, multivariable analysis
Monthly exposure to aggressive regimen 0.63 0.43, 0.93
Received #2 previous regimens without CER 0.43 0.25, 0.74
Female 1.45 1.02, 2.07
Age 1.01 1.00, 1.03
Low BMI or malnutrition 2.45 1.63, 3.68
Tachycardia 2.19 1.50, 3.19
Extrapulmonary TB 1.68 1.05, 2.68
At least one comorbidity, other than HIV 1.71 1.21, 2.43
HIV Infection 2.72 1.03, 7.24
Number of resistant agents 1.03 0.92, 1.15
doi:10.1371/journal.pone.0058664.t004
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the present study adds that benefits may also accrue through use of
aggressive regimens for MDR-TB.
In addition, the algorithmic approach examined in this study
provides useful guidance for TB programs and supplements global
guidelines. Current WHO recommendations [13,43] call for
‘‘…four second-line anti-tuberculosis drugs likely to be effective
(including a parenteral agent), as well as pyrazinamide…’’ This
was based on an analysis that tried to elucidate the role of
individual drugs and a simple minimum number of drugs.
Approaching the problem differently, our analysis revealed that
a regimen containing five likely effective drugs reduced the risk of
death in this population of patients with extensive prior treatment.
Use of this algorithmic approach may provide additional options
for composing aggressive regimens in settings in which the specific
drugs recommended in the Guidelines are not available, or when
pyrazinamide is not a likely effective drug.
Improving the success of MDR-TB treatment with existing
drugs is essential. Results achieved to date have been far from
optimal: pooled estimates indicate that only 62% (57%–67%) of
patients treated had favorable outcomes. [38,44].
With multiple new compounds in the drug-development
pipeline, truly optimized regimens are also critical as comparator
background regimens in trials. The consequence of use of a sub-
optimal background regimen for MDR-TB treatment was illustrat-
ed in a study of a new anti-TB agent: only 9% of the placebo
group experienced sputum culture conversion after two months of
treatment; [45] this is considerably lower than in other reports of
MDR-TB treatment. [46,47] Although there may be other
explanations for this relatively low conversion frequency (i.e.,
MGIT culture system, more extensive parenchymal damage),
insufficient efficacy of the background regimen cannot be
excluded.
The aggressive regimen described in the present study could be
used as a background regimen and comparator in studies of new
drugs. This would afford greater protection to patients with more
extensive prior exposure than does a standardized regimen whose
efficacy was demonstrated in a population without prior exposure
to second-line drugs or known HIV infection. [48] The quality of
studies of new drugs to treat MDR-TB will be enhanced
immediately by incorporating novel evidence such as that we
report here, which can guide construction of an optimized
background regimen.
As in other retrospective studies, the potential for unmeasured
confounding exists. Since patients were not deliberately (randomly
or otherwise) assigned to non-aggressive regimens, we cannot rule
out the possibility that the patients receiving and not receiving
aggressive regimens differed in ways that also influenced the risk
for death. Controlling for indicators of disease severity and
comorbidities likely reduced the possibility of such confounding.
Adverse events, however, were not recorded routinely and may
have been linked both to the inability to construct an aggressive
regimen and to the risk of death. This potential link should be
evaluated in future, prospective studies. With respect to the
exposure variable, although its time-varying assignment reduces
misclassification, some potential for misclassification remains. This
is because the definition of aggressive allows that drugs not
previously received, and for which sensitivity testing had not been
performed, are considered to contribute to an aggressive regimen.
This risk of misclassification is greatest for the fluoroquinolones
and injectables for which there is at least partial cross-resistance
among members of the class. [49,50,51,52,53] If treatment months
are misclassified as aggressive when they contain drugs to which
patient isolates are resistant, this would likely bias the effect
estimate towards the null (i.e., make the aggressive regimen seem
less protective than it is). Lastly, we note that this study was
conducted in a population with significant prior treatment
exposure, and may represent a survival cohort. It is impossible,
however, to assess the effect of survivor bias on treatment
outcomes without having a comparison group–that is, MDR-TB
patients who had not received prior treatment; of note only two
patients in this study had received no prior treatment for TB.
Since, under program conditions, therapy for MDR-TB is often
reserved for patients who have received repeated treatments for
TB, our results can be generalized to many patient populations
treated in low- to middle-income countries. And, as noted above,
our results indicate that prior exposure should be limited in order
to facilitate composition of an aggressive regimen and reduce the
risk of death.
In conclusion, these findings support the early use of an
aggressive regimen for MDR-TB. The use of such regimens
improves patient outcomes and is essential to stem the epidemic of
multi-drug resistance, which affects roughly one-half million new
TB patients annually. [54,55,56] Treating MDR-TB patients with
sub-standard regimens likely fuels the development of even more
resistant strains, leading to the predictable tragedy making news
most recently: strains resistant to all drugs tested. [57,58,59].
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